Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis

Therapeutic Drug Monitoring

Volumn 29, Issue 6, 2007, Pages 750-757

  Punnett, Angela ^a,b   Sung, Lillian ^a,b,c   Price, Victoria ^d   Das, Prabodh ^a   Diezi, Manuel ^a   Doyle, John ^a,c   Dupuis, L Lee ^a,b,e  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cyclosporine; Graft versus host disease; Hematopoietic stem cell transplantation; Methotrexate; Prophylaxis

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUCONAZOLE; FOLINIC ACID; GANCICLOVIR; IMMUNOGLOBULIN; METHOTREXATE; PHENYTOIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVER TOXICITY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; MYCOSIS; NEPHROTOXICITY; PHYSICIAN; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL; UNIVARIATE ANALYSIS; WHOLE BODY RADIATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG MONITORING; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LOGISTIC MODELS; MALE; METHOTREXATE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 36549060242     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31815c12ca     Document Type: Article

References (60)

1. Pession A, Locatelli F, Zecca M, et al. Cyclosporine-A as GVHD prophylaxis in allogeneic BMT for childhood acute leukemia. AIEOP-BMT group. Bone Marrow Transplant. 1998;21(Suppl 2):S50-S52.
2. Locatelli F, Uderzo C, Dini G, et al. Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A. Bone Marrow Transplant. 1993;12:627-633.
3. Basara N, Blau IW, Willenbacher W, et al. New strategies in the treatment of graft-versus-host disease. Bone Marrow Transplant. 2000;25(Suppl 2):S12-S15.
4. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood. 1991;77:1821-1828.
5. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
6. Gratwohl A, Hermans J, Apperley J, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood. 1995;86:813-818.
7. Ringden O, Hermans J, Labopin M, et al. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Leuk Lymphoma. 1996;24:71-79.
8. Ruutu T, Niederwieser D, Gratwohl A, et al. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant. 1997;19:759-764.
9. Peters C, Ladenstein R, Minkov M, et al. Transplantation activities and treatment strategies in paediatric stem cell transplantation centres: a report from the EBMT Working Party on Paediatric Diseases. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998;22:431-437.
10. Peters C, Minkov M, Gadner H, et al. Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transplant. 2000;26:405-411.
11. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood. 1989;73:1729-1734.
12. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729-735.
13. Ringden O, Horowitz MM, Sondel P, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood. 1993;81:1094-1101.
14. Anasetti C, Hansen JA. Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors. Transfusion Sci. 1994;15:221-230.
15. Beatty PG, Hansen JA, Longton GM, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation. 1991;51:443-447.
16. Yee GC, Self SG, McGuire TR, et al. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med. 1988;319:65-70.
17. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 1992;80:1838-1845.
18. Santos GW, Tutschka PJ, Brookmeyer R, et al. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant. 1987;1:21-28.
19. Martin P, Bleyzac N, Souillet G, et al. Relationship between CSA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant. 2003;32:777-784.
20. Byrne J, Stainer C, Hyde H, et al. Low incidence of acute graft-versus-host disease and recurrent leukemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Bone Marrow Transplant. 1998;22:541-545.
21. Przepiorka D, Shapiro S, Schwinghammer TL, et al. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease. Bone Marrow Transplant. 1991;7:461-465.
22. Wingard JR, Nash RA, Przepiorka D, et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant. 1998;4:157-163.
23. Ghalie R, Fitzsimmons WE, Weinstein A, et al. Cyclosporine monitoring improves graft-versus-host disease prophylaxis after bone marrow transplantation. Ann Pharmacother. 1994;28:379-383.
24. Schmidt H, Ehninger G, Dopfer R, et al. Correlation between low CSA plasma concentration and severity of acute GvHD in bone marrow transplantation. Blut. 1988;57:139-142.
25. Bandini G, Strocchi E, Ricci P, et al. Ciclosporin A: correlation of blood levels with acute graft-versus-host disease after bone marrow transplantation. Acta Haematol. 1987;78:6-12.
26. Bogdanic V, Mrsic M, Plavsic F, et al. Blood cyclosporine concentration and risk of acute GVHD after allogeneic bone marrow transplantation [Abstract]. Bone Marrow Transplant. 1988;3(Suppl 2):67.
27. Barrett AJ, Kendra JR, Lucas CF, et al. Cyclosporin A as prophylaxis against graft-versus-host disease in 36 patients. BMJ. 1982;285:162-166.
28. Gratwohl A, Speck B, Wenk M, et al. Cyclosporine in human bone marrow transplantation. Serum concentration, graft-versus-host disease, and nephrotoxicity. Transplantation. 1983;36:40-44.
29. Lindholm A, Ringden O, Lonnqvist B. The role of cyclosporine dosage and plasma levels in efficacy and toxicity in bone marrow transplant recipients. Transplantation. 1987;43:680-684.
30. Britton K, Atkinson K, Downs K, et al. The correlation of cyclosporine serum and whole blood concentrations with toxicity and efficacy after human marrow transplantation. Transplant Proc. 1985;17:1667-1670.
31. McGuire TR, Yee GC, Emerson S, et al. Pharmacodynamic studies of cyclosporine in marrow transplant recipients. A comparison of three assay methods. Transplantation. 1992;53:1272-1275.
32. Martin P, Bleyzac N, Souillet G, et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant. 2003;32:881-887.
33. Duncan N, Craddock C. Optimizing the use of cyclosporin in allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38:169-174.
34. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
35. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295-304.
36. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc. 1958;53:457-481.
37. Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood. 1991;77:1423-1428.
38. Bacigalupo A, Vitale V, Corvo R, et al. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Br J Haematol. 2000;108:99-104.
39. Michallet M, Perrin MC, Belhabri A, et al. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;23:145-150.
40. Locatelli F, Bruno B, Zecca M, et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood. 2000;96:1690-1697.
41. Teuffel O, Schrauder A, Sykora KW, et al. The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia. Bone Marrow Transplant. 2005;36:145-150.
42. Kanda Y, Izutsu K, Hirai H, et al. Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. Leukemia. 2004;18:1013-1019.
43. Kanda Y, Hyo R, Yamashita T, et al. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor. Am J Hematol. 2006;81:838-844.
44. Oellerich M, Armstrong VW, Kahan B, et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit. 1995;17:642-654.
45. Mori T, Nakazato T, Aisa Y, et al. Prophylaxis of graft-versus-host- disease (GVHD) with tacrolimus and methotrexate after allogeneic bone marrow transplantation (BMT) from unrelated donor: impact of blood level of tacrolimus on the development of acute GVHD [Abstract]. Biol Blood Marrow Transplant. 2006;12(Suppl):65.
46. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95:2754-2759.
47. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13:136-142.
48. Ferrara JLM. GVHD: in vivo veritas. Blood. 2005;106:772-773.
49. Levy G, Thervet E, Lake J, et al. Patient management by Neoral C2 monitoring: an international consensus statement. Transplantation. 2002;73(Suppl):S12-S18.
50. Nashan B, Cole E, Levy G, et al. Clinical validation studies of Neoral C2 monitoring: a review. Transplantation. 2002;73(Suppl 9):S3-S11.
51. Trompeter R, Fitzpatrick M, Hutchinson C, et al. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (NeoralTM) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. Pediatr Transplant. 2003;7:282-288.
52. Morris RG, Russ GR, Cervelli MJ, et al. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit. 2002;24:479-486.
53. Ferraresso M, Ghio L, Zacchello G, et al. Pharmacokinetic of cyclosporine microemulsion in pediatric kidney recipients receiving a quadruple immunosuppressive regimen: the value of C2 blood levels. Transplantation. 2005;79:1164-1168.
54. Dupuis LL, Taylor T, Saunders EF. Cyclosporine disposition in pediatric hematopoietic stem cell transplantation patients after IV and oral administration [Abstract]. Biol Blood Marrow Transplant. 2005;11:106.
55. Dupuis LL, Taylor T, Saunders FE. Disposition of two oral formulations of cyclosporine in pediatric patients receiving hematopoietic stem cell transplants. Pharmacotherapy. 2006;26:1-22.
56. Hendriks MP, Blijlevens NM, Schattenberg AV, et al. Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2006;38:521-525.
57. Duncan N, Craddock C. Optimizing the use of cyclosporin in allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38:169-174.
58. Russell JA, Woodman RC, Poon MC, et al. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease. Bone Marrow Transplantation. 1994;14:397-401.
59. Nevill TJ, Tirgan MH, Deeg HJ, et al. Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation [see comment]. Bone Marrow Transplant. 1992;9:349-354.
60. Svennilson J, Remberger M, Ringden O. Risk factors for moderate-to-severe acute graft-vs.-host disease after allogeneic stem cell transplantation in children. Pediatr Transplant. 2003;7:130-136.